Boston Scientific invests in bioresorbable stent maker; Tandem Diabetes Care pursues voluntary recall;

@FierceMedDev: JPM 2014: GlySure CEO hits SF to advance the company's ICU glucose monitoring device. Editor's Corner | Follow @FierceMedDev

@MarkHFierce: Phillips is in trouble with the FDA, in part, for conducting a recall and not informing regulators about the details. Warning letter | Follow @MarkHFierce

@MichaelGFierce: Roche's delivery method 'shuttles' Alzheimer's drugs past blood-brain barrier. More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Hate getting shots? You might be able to try this painless drug injector soon. Article | Follow @EmilyWFierce

@GalenMoore: Covidien puts Almeida's JPM '14 words into practice with a brace of deals in emerging markets. Report | Follow @GalenMoore

> Boston Scientific ($BSX) is investing an undisclosed amount of cash in Amaranth Medical, a California developer of a drug-eluting bioresorbable scaffold on the verge of an international clinical study. Item

> Newly public Tandem Diabetes Care ($TNDM) has issued a voluntary recall of more than 4,700 boxes of insulin pump cartridges after determining a potential leak risk. Story

> Alere ($ALR) Connect gained both a 510(k) clearance and CE mark to market HomeLink, a device that can help transmit patient data to doctors via the cloud. Item

> Medite Group, a Florida developer of equipment and supplies for cancer diagnostics, has agreed to be acquired by Chicago's CytoCore. Story

> California's Onciomed has raised a $5.5 million Series A financing to begin human trials of an implantable antiobesity device billed as a less invasive alternative to bariatric surgery. Story

Biotech News

@FierceBiotech: Jazz bets up to $397M on Aerial's narcolepsy drug. Story | Follow @FierceBiotech

@JohnCFierce: I predict that today we'll move from deal talk to bold CEO projections at JPMorgan 2014. It is a fun spectator sport. | Follow @JohnCFierce

@DamianFierce: For its next trick, Moderna splits in two with $20M cancer venture. News | Follow @DamianFierce

@EmilyMFierce: Investigators find a way to keep stem cells' options open until they're needed. More | Follow @EmilyMFierce

> Bristol-Myers looks to rival Gilead for the key to conquering the hep C market. More

> Allergan CEO preps multibillion-dollar deal spree to swell pipeline. News

> Regeneron, Bayer reach for the old Eylea magic with combo AMD deal. Article

> AstraZeneca's Soriot faces off against skeptics, preaches late-stage R&D revival. Coverage

Pharma News

@FiercePharma: Valeant, Mylan, and Actavis eye Pfizer's brand-new generics unit for buyout: Reuters. Story | Follow @FiercePharma

@TracyStaton: Top story at FiercePharma Monday: Look for an M&A scramble as pharma cash chases higher prices. Story | Follow @TracyStaton

@EricPFierce: India's Aurobindo is looking for more sterile injectable capacity and Actavis has some in the EU for sale. Deal? Story from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Chinese corruption probe expands as officials detain former Sinopharm exec. More | Follow @CarlyHFierce

> Novartis generic squares off with Glaxo's Advair in third EU country. Item

> AstraZeneca sees earlier patent-cliff recovery, thanks to $4 billion diabetes buyout. Article

> FDA hands pharma marketers another piece of social-media guidance. Story

> Merck CEO: We'll decide fate of animal health, consumer biz by year's end. More

Biotech Research News

> Embryonic-like stem cells created from frozen tissue of Alzheimer's patients. More

> Scientists capture key protein structures that could aid malaria vaccine design. News

> Low doses of cancer drug prevent Type 1 diabetes in mice. Story

> Investigators find a way to keep stem cells' options open until they're needed. Article

> Mimetas, Galapagos partner on organs-on-chip technology. Piece

> European industry-academic partnership seeks miRNA therapies for neurodegenerative diseases. Item

Pharma Manufacturing News

> 11 compounders tell the FDA to bring it on. Report

> Aurobindo is looking to buy API plants from Actavis. More

> China corruption probe takes a turn into domestic drug distribution business. News

> Ranbaxy manufacturing drama continues with FDA action on API plant. Story

> McKesson recalibrates its EU strategy after Celesio deal nosedives. Article

> Wockhardt hires a new compliance exec in the face of FDA bans. Item

Suggested Articles

J.D. Power aims to set the benchmarks in telehealth satisfaction with a new study due this November.

Atomwise plans to screen up to 10 billion virtual compounds for therapies against childhood cancer in collaboration with chemical supplier Enamine.

The Chan Zuckerberg Initiative set aside $68 million for over three dozen projects in an effort to map out every type of cell in the body.